What question did this study set out to answer?

To determine whether the false-negative rate of sentinel lymph node surgery is 10% or less following neoadjuvant chemotherapy in women presenting with biopsy-proven node-positive (cN1) breast cancer.

November 3, 2020Open Access

Sentinel Lymph Node Surgery After Neoadjuvant Chemotherapy in Patients With Node-Positive Breast Cancer: The ACOSOG Z1071 (Alliance) Clinical Trial

View Full Paper

Ask AI

Bookmark

Authors

JBJudy C. BougheyMayo Clinic

Discussion

Member takes

Implication

Multicenter trial reveals an elevated false-negative rate for sentinel node surgery after chemotherapy in node-positive breast cancer, indicating refinement is required before replacing dissection.

Key Points

To determine whether the false-negative rate of sentinel lymph node surgery is 10% or less following neoadjuvant chemotherapy in women presenting with biopsy-proven node-positive (cN1) breast cancer.
Multicenter prospective clinical trial enrolling 756 women with clinical T0-T4, N1-N2, M0 breast cancer receiving neoadjuvant chemotherapy across 136 institutions.
Following chemotherapy, 649 evaluable patients with cN1 disease underwent both sentinel lymph node surgery (with dual-agent mapping encouraged) and completion axillary lymph node dissection.
Among 525 patients with 2 or more sentinel lymph nodes examined, the pathological complete nodal response rate was 41.0% (95% CI, 36.7%-45.3%).
Cancer was missed in the sentinel lymph nodes but detected on axillary dissection in 39 patients, producing a false-negative rate of 12.6% (90% Bayesian credible interval, 9.85%-16.05%), which exceeded the target 10% threshold.

Cite This Study

Judy C. Boughey (2020) studied this question.

synapsesocial.com/papers/6a86d1b4cbde9db34bcb8cdd https://doi.org/10.17615/34jp-0g23

View Full Paper

Ask AI

Bookmark

Implication

Multicenter trial reveals an elevated false-negative rate for sentinel node surgery after chemotherapy in node-positive breast cancer, indicating refinement is required before replacing dissection.

Sentinel Lymph Node Surgery After Neoadjuvant Chemotherapy in Patients With Node-Positive Breast Cancer: The ACOSOG Z1071 (Alliance) Clinical Trial

Discussion

Member takes

Implication

Key Points

Cite This Study

Sentinel Lymph Node Surgery After Neoadjuvant Chemotherapy in Patients With Node-Positive Breast Cancer: The ACOSOG Z1071 (Alliance) Clinical Trial

Discussion

Member takes

Implication

Key Points

Cite This Study

Also Consider

Also Consider